Edwards Lifesciences' PASCAL system shows superiority over medical therapy in CLASP II TR trial

Edwards Lifesciences reported that its PASCAL system for tricuspid repair showed superiority compared to medical therapy alone on the six-month primary endpoint of the CLASP II TR trial.

Detected & updated continuously · Source: Nebula